The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment
- PMID: 12705498
- DOI: 10.1023/a:1022935115323
The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment
Abstract
Mucolipidosis type III (ML III; McKusick 252600) is a rare lysosomal storage disease in which skeletal involvement is prominent, in particular the destruction of vertebral bodies and the femoral heads. We describe studies in two siblings with ML III that suggest the presence of a distinct metabolic bone disorder. Biochemical indices of bone turnover were increased, and transiliac bone biopsy demonstrated both trabecular osteopenia and marked subperiosteal bone resorption. Intravenous pamidronate treatment given monthly for a year was well tolerated and produced dramatic clinical effects, with reduction in bone pain and improvements in mobility, despite incomplete suppression of bone resorption as assessed by biochemical, radiographic and histological criteria. Bisphosphonate therapy may have an important role in the management of bone pain in ML III, as it does in the related lysosomal disorder of Gaucher disease.
Similar articles
-
Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate).Q J Med. 1991 Jun;79(290):503-15. Q J Med. 1991. PMID: 1946931
-
Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.Bone. 2004 Jul;35(1):235-42. doi: 10.1016/j.bone.2004.03.004. Bone. 2004. PMID: 15207763
-
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.J Bone Miner Res. 1997 Oct;12(10):1746-52. doi: 10.1359/jbmr.1997.12.10.1746. J Bone Miner Res. 1997. PMID: 9333137 Clinical Trial.
-
Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.J Bone Miner Res. 2004 May;19(5):703-11. doi: 10.1359/JBMR.040127. Epub 2004 Jan 19. J Bone Miner Res. 2004. PMID: 15068492 Review.
-
Bisphosphonates and breast carcinoma.Cancer. 1997 Oct 15;80(8 Suppl):1668-73. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1668::aid-cncr17>3.3.co;2-5. Cancer. 1997. PMID: 9362434 Review.
Cited by
-
Mucolipidosis type III, a series of adult patients.J Inherit Metab Dis. 2018 Sep;41(5):839-848. doi: 10.1007/s10545-018-0186-z. Epub 2018 Apr 27. J Inherit Metab Dis. 2018. PMID: 29704188 Free PMC article.
-
Pathogenic variants in GNPTAB and GNPTG encoding distinct subunits of GlcNAc-1-phosphotransferase differentially impact bone resorption in patients with mucolipidosis type II and III.Genet Med. 2021 Dec;23(12):2369-2377. doi: 10.1038/s41436-021-01285-9. Epub 2021 Aug 2. Genet Med. 2021. PMID: 34341521 Free PMC article.
-
Elevated Bone Turnover in an Infantile Patient with Mucolipidosis II; No Association with Hyperparathyroidism.Clin Pediatr Endocrinol. 2011 Jan;20(1):7-12. doi: 10.1297/cpe.20.7. Epub 2011 Mar 26. Clin Pediatr Endocrinol. 2011. PMID: 23926388 Free PMC article.
-
Mucolipidosis type III α/β: the first characterization of this rare disease by autopsy.Arch Pathol Lab Med. 2011 Apr;135(4):503-10. doi: 10.5858/2010-0236-CR.1. Arch Pathol Lab Med. 2011. PMID: 21466370 Free PMC article.
-
Enlarged follicles and temporomandibular joint abnormalities in mucolipidosis Type III.Dentomaxillofac Radiol. 2013;42(4):22822014. doi: 10.1259/dmfr/22822014. Epub 2012 Jan 12. Dentomaxillofac Radiol. 2013. PMID: 22241869 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical